OCULAR THERAPEUTIX INC (OCUL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for OCUL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| OCUL | Director | 70 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| WTS | Director; Chairperson | 70 | ["Chief Financial Officer of IDEXX Laboratories, Inc. from October 2003 to May 2013", "Executive Vice President of IDEXX from July 2012 to May 2013", "Corporate Vice President of Finance", "Vice President of Finance and Treasurer", "Director of Finance", "Controller", "Board member of Aratana Therapeutics, Inc. from February 2014 to July 2019", "Board member of Benchmark Electronics, Inc. from May 2018 to June 2021", "Board member of TransMedics Group, Inc. since January 2021", "Board member of Ocular Therapeutix, Inc. since September 2021", "audit committee financial expert", "Operational Experience developing and implementing operating plans and business strategy", "Finance/Capital Allocation", "Mergers & Acquisitions", "Supply Chain/Logistics", "Digital/eCommerce", "Marketing/Sales & Brand Management"] | ["Audit Committee", "Governance and Sustainability Committee"] | 2026 |
| TMDX | Director; Chairperson of the Audit Committee | ["audit committee financial expert","sufficient knowledge in financial and auditing matters"] | ["Audit Committee"] | 2026 | |
| BHE | Director | 65 | ["Retired Chief Financial Officer of IDEXX Laboratories, Inc."] | [] | 2021 |
| IDXX | Former Executive Vice President and Chief Financial Officer | [] | [] | 2014 |
Biography sourced from the proxy statement filing.
Merilee Raines has served as a member of our board of directors since September 2021. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc. from October 2003 until her retirement in May 2013. Ms. Raines also served as Executive Vice President of IDEXX from July 2012 until her retirement in May 2013. Prior to becoming Chief Financial Officer, Ms. Raines held several management positions with IDEXX, including Corporate Vice President of Finance, Vice President of Finance and Treasurer, Director of Finance, and Controller. Ms. Raines has served as a member of the boards of directors of Watts Water Technologies, Inc., a publicly-traded global supplier of water technologies and solutions, since February 2011; Excelitas Technologies Corporation, a privately-held photonics company providing sensing and detecting solutions, since August 2018; and TransMedics Group, Inc., a publicly-traded commercial stage medical technology company, since January 2021. She also served as a member of the board of directors of Benchmark Electronics, Inc., a publicly-traded worldwide provider of engineering services, integrated technology solutions and electronic manufacturing services, from May 2018 to June 2021 and Aratana Therapeutics, Inc., a publicly-traded veterinary therapeutics company, from February 2014 until its acquisition in July 2019. Ms. Raines has extensive executive leadership, accounting and finance, operations and strategy; risk management; corporate governance; medical technology development and commercialization; and life sciences industry experience. We believe that Ms. Raines is qualified to serve on our board of directors for these reasons.